Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. - Test2 - elhamkhani - TriplyDB

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

http://www.wikidata.org/entity/Q30620671

about

Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations Efficacy of tiotropium-olodaterol fixed-dose combination in COPD A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.Tiotropium formulations and safety: a network meta-analysis Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial.Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm.Tiotropium safety in 'real-world' populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology Defining the relationship between COPD and CVD: what are the implications for clinical practice?Muscarinic Receptor Antagonists.Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.

P2860

Q28067579-D9F1719E-119A-438F-A0DA-22B19E4ABE56 Q28075367-3AC21B9C-B6FD-4EBC-AC0B-B5555605CA52 Q30820402-085571D3-CCB8-4D78-AC2A-40BAC23B2F4B Q33590384-460BA2E5-A6BD-422E-8A6C-C17D2616809A Q37315758-A924079C-FE11-42DD-8764-8285AA54AC3F Q37446886-BF71433B-3855-4A84-AE93-9E8EF2F9475B Q38833618-4C8276C4-02FE-4DFF-9EDD-643FC4791062 Q38871993-9FD4493A-D4F9-46D8-910E-D4268DDB9460 Q39137733-83F7176D-2FCB-4981-AD1D-CF2461266C7A Q40966874-C84DF6D7-8BD6-422E-B8DB-41AB8E279F11 Q42291048-8E736FB1-BB0C-4797-97A3-932597E28650 Q42382857-2C3D9B64-64A7-4EA9-B4DC-1DDDB6419C7C Q47651592-783866D2-64EA-49D3-B0E4-66D0C0C1497F Q51432583-D93F2CA2-DC85-43C2-875C-F8A326B95F04 Q55133367-59B8936B-052F-4927-A042-4D7C1DA80363

P2860

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

http://www.wikidata.org/entity/Q30620671

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@ast

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@en

type

label

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@ast

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@en

prefLabel

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@ast

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@en

P1433

Q30620671-2A9C6E12-DBEC-4A9D-ABBF-C00C9E8B78D8

P1476

Q30620671-540CA361-E319-4ECF-A6A9-826B2F0AC009

P2093

Q30620671-1FAE4388-83EC-49A0-B20D-A1746E2FBB73

Q30620671-545AB99C-3F06-4A16-8539-9942668C1942

Q30620671-6AEEBD93-B77C-4D8C-BF93-269DCBDDB6FE

Q30620671-B9120531-C168-46B5-A849-D97E419DB063

Q30620671-BC21DA43-E6EA-4151-907E-611E201BB61E

P2860

Q30620671-0197166C-8250-4D46-906F-FCA5F82FC1F3

Q30620671-034A096D-C275-41AE-8196-92154151A31E

Q30620671-04AEC278-FAF0-40F8-B020-00B4E1846074

Q30620671-06B209CC-68E5-4115-BBCA-919E9CEAA0F6

Q30620671-1132976B-BA87-4A07-94EC-CEA68A481870

Q30620671-11D92E82-B1E7-4E13-A3AA-04397555986A

Q30620671-12597E01-50E9-4695-9B85-E3208A7366CD

Q30620671-1D374AC3-31B6-446A-9815-A7D8C346ED9B

Q30620671-225C5AB8-5F5D-43BE-B740-BC6777EC8DD2

Q30620671-229EF9D5-0264-4812-8CEB-A253F056FC91

P304

Q30620671-E303593F-A79B-41A5-869B-52AA009923CB

P31

Q30620671-4155a84e-08cb-4217-9d33-58420adf99d8

Q30620671-970B6476-4E74-4CC0-B03E-0ED302C5E4C8

P356

Q30620671-8A35C93F-03F5-4F85-8BF0-330723D0C10D

P407

Q30620671-794AE117-1053-412E-903E-CDFF3F926350

P478

Q30620671-DBE0EEB0-8900-4CFE-8E8B-53ABA13E6FA7

P577

Q30620671-EFC5AAAA-872B-4757-9AAF-E20C8B4BA82C

P698

Q30620671-066DBE94-C389-4047-9234-D3044E0DA754

P921

Q30620671-11A06F2B-3304-4DB6-99A9-81F57190CEC2

P932

Q30620671-A1FAD343-9D74-41DD-95AE-03229A9C4E8C

P356

P1433

International Journal of Chronic Obstructive Pulmonary Disease

P1476

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

@en

P2093

Achim Mueller

http://www.w3.org/2001/XMLSchema#string

Christoph Hallmann

http://www.w3.org/2001/XMLSchema#string

David Mg Halpin

http://www.w3.org/2001/XMLSchema#string

Donald Tashkin

http://www.w3.org/2001/XMLSchema#string

Ronald Dahl

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Tiotropium versus placebo for chronic obstructive pulmonary disease

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

The effect of tiotropium on exacerbations and airflow in patients with COPD.

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.

Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date.

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study.

P304

239-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S75146

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25709423

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

4332287

http://www.w3.org/2001/XMLSchema#string